Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas

L. Zlamalikova, M. Moulis, D. Salek, J. Jarkovsky, J. Smarda, J. Smardova,

. 2016 ; 35 (5) : 2673-2680. [pub] 20160307

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000339

Grant support
NT13784 MZ0 CEP Register

D-type cyclins are involved in cell cycle regulation and play an important role in the pathogenesis of lymphomas. Aberrant expression of cyclin D1 is associated with mantle cell lymphoma (MCL) and serves as a diagnostic marker of MCL. Analysis of cyclin D expression in tumor tissues of patients with diffuse large B-cell lymphoma (DLBCL) which comprises a heterogeneous group of tumors may contribute to their stratification. We analyzed expression of cyclin D1, D2, and D3 mRNAs in 30 MCL and 104 DLBCL patients using qRT-PCR and addressed their significance for disease outcome. We confirmed a high level of cyclin D1 mRNA in 29 MCL cases (97%). One case (3%) was identified as positive for cyclin D2. Expression of cyclin D1 was limited to MCL and did not occur in DLBCL. Overexpression of cyclin D2, which is rare in MCL, occurred more frequently in DLBCL (11 cases, 10.6%). We showed that high expression of cyclin D2 in DLBCL cases de novo decreased the overall survival rate (P=0.016) and progression-free survival (P=0.009). The expression pattern of cyclin D3 was similar in both types of studied lymphomas and it did not affect the disease outcome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000339
003      
CZ-PrNML
005      
20191022083758.0
007      
ta
008      
170103s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/or.2016.4658 $2 doi
024    7_
$a 10.3892/or.2016.4658 $2 doi
035    __
$a (PubMed)26985765
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Zlamalikova, Lenka $u Department of Pathology, University Hospital, 625 00 Brno, Czech Republic.
245    10
$a Expression of D-type cyclins in mantle cell and diffuse large B-cell lymphomas / $c L. Zlamalikova, M. Moulis, D. Salek, J. Jarkovsky, J. Smarda, J. Smardova,
520    9_
$a D-type cyclins are involved in cell cycle regulation and play an important role in the pathogenesis of lymphomas. Aberrant expression of cyclin D1 is associated with mantle cell lymphoma (MCL) and serves as a diagnostic marker of MCL. Analysis of cyclin D expression in tumor tissues of patients with diffuse large B-cell lymphoma (DLBCL) which comprises a heterogeneous group of tumors may contribute to their stratification. We analyzed expression of cyclin D1, D2, and D3 mRNAs in 30 MCL and 104 DLBCL patients using qRT-PCR and addressed their significance for disease outcome. We confirmed a high level of cyclin D1 mRNA in 29 MCL cases (97%). One case (3%) was identified as positive for cyclin D2. Expression of cyclin D1 was limited to MCL and did not occur in DLBCL. Overexpression of cyclin D2, which is rare in MCL, occurred more frequently in DLBCL (11 cases, 10.6%). We showed that high expression of cyclin D2 in DLBCL cases de novo decreased the overall survival rate (P=0.016) and progression-free survival (P=0.009). The expression pattern of cyclin D3 was similar in both types of studied lymphomas and it did not affect the disease outcome.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a cyklin D $x genetika $x metabolismus $7 D056741
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a exprese genu $7 D015870
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a difúzní velkobuněčný B-lymfom $x metabolismus $x mortalita $7 D016403
650    _2
$a lymfom z plášťových buněk $x metabolismus $x mortalita $7 D020522
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Moulis, Mojmír $u Department of Pathology, University Hospital, 625 00 Brno, Czech Republic. $7 xx0121681
700    1_
$a Šálek, David $u Department of Hematooncology, University Hospital, 625 00 Brno, Czech Republic. $7 xx0211647
700    1_
$a Jarkovský, Jiří, $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. $d 1976- $7 stk2008461294
700    1_
$a Šmarda, Jan, $u Department of Experimental Biology, Faculty of Science, Masaryk University, 611 37 Brno, Czech Republic. $d 1961- $7 mzk2006343362
700    1_
$a Šmardová, Jana, $u Department of Pathology, University Hospital, 625 00 Brno, Czech Republic. $d 1961- $7 mzk2005304278
773    0_
$w MED00179060 $t Oncology reports $x 1791-2431 $g Roč. 35, č. 5 (2016), s. 2673-2680
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26985765 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20191022084232 $b ABA008
999    __
$a ok $b bmc $g 1179479 $s 960906
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 35 $c 5 $d 2673-2680 $e 20160307 $i 1791-2431 $m Oncology reports $n Oncol Rep $x MED00179060
GRA    __
$a NT13784 $p MZ0
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options